BUSINESS

• JCR Launches PIII Study of Growject for SHOX Deficiency
  July 3, 2018

• Sawai President Shows Eagerness to “Take Over” To-Be-Withdrawn LLPs
  July 2, 2018

• With Focus on CGRP, Development of New Generation of Preventive Treatments for Migraines Heating Up
  July 2, 2018

• Baxalta Appeals to IP High Court in Hemlibra Patent Lawsuit against Chugai
  July 2, 2018

• Weber Earns 1.2 Billion Yen in FY2017, Logging Western-Level Pay Ratio
  June 29, 2018

• Grilled by Shareholders, Takeda CEO Seeks Understanding for Shire Deal
  June 29, 2018

• AstraZeneca, MSD to Copromote Lynparza from July
  June 29, 2018

• Nippon Shinyaku’s Sakigake-Designated DMD Med Boosts Dystrophin Protein Production in Clinical Studies
  June 29, 2018

• BMS Ties Up with Nagoya Univ. for Immuno-Oncology Biomarker Research
  June 29, 2018

• Eliquis Significantly Lowers Stroke Risk vs Warfarin: Real-World Data
  June 29, 2018

• Mitsubishi Tanabe, Janssen Revise Copromotion Framework for Stelara
  June 29, 2018

• JT, Torii Ditch Pruritus Candidate Development
  June 29, 2018

• Takeda Shareholders Strike Down Dissident Group’s Proposal
  June 28, 2018

• Japan’s 1st Rituxan Biosimilar Boasts 13% Share: Sandoz Country Head
  June 28, 2018

• DPP-4/SGLT2 Combo Sujanu Most Heavily Pitched for GPs in May: Anterio
  June 28, 2018

• AbbVie Eyes Global Simultaneous Launch for Autoimmune Disease Treatments: Exec
  June 28, 2018

• Keytruda’s MSI-H Cancer Indication to Be Reviewed Under Conditional Early Approval System
  June 28, 2018

• Chugai Chairman Prods Drug Makers to Innovate, Chides Calls for Relaxed Pricing
  June 27, 2018

• FDA Decision on Shionogi’s Single-Dose Drug Expected by Dec. 24
  June 27, 2018

• Rohto Takes 15% Stake in Shionogi’s Consumer Healthcare Unit
  June 26, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 380
• 381
• 382
• 383
• 384
• 385
• 386
• 387
• 388
• …
• Next ›
• 最終 »